Have traded this stock over the past few years and made some...

Have traded this stock over the past few years and made some decent money along the way. With the company actively recruiting patients for its landmark Alzheimer's Phs2 trials i have re-entered this stock over the past few months and will continue to build on my position. Doctors and media have been talking up the Alzheimer's space recently and i believe any stock that has potential in the space will have significant upside with ACW a serious contender. With Xanamem's key ability to reduce the stress chemical cortisone in the brain this drug may well be a massive player in the Alzheimer's space. The below quote by Professor Jeffrey Cummings, M.D dDirector of the Cleveland Clinic Lou Center for Brain Health in the US about the potential of Xanamem says it all on the potential that ACW presents.

“This [XanADu] is one of the most significant studies that I have been involved in as it could provide the turning point needed in finding a new effective treatment for Alzheimer’s disease. Given the compelling evidence linking raised cortisol and the development of Alzheimer’s disease, the global medical community will be closely following this clinical trial,” he said.

With the upcoming Bioshares conference in NZ i expect there to be rekindled interest in the bio sector with Alzheimer's one of the hot spaces that will put ACW in the spotlight as a potential significant player in the field. This could see investors hungry for a company like ACW that sits well below peers in the Alzheimer's space globally that has significant upside potential. Not only from an investor point but the significant upside for ACW could see large pharma prepared to pay in the 100s of millions in upfront payments to ACW while in phs2 trials.

Dr Bill Ketelbey Actinogen's CEO and former CEO of Pfizer Aus was recently at a US bio conference and met with Pfizer. Not forgetting he was involved with taking Aricept the key Alzheimer's drug currently on the market all the way to commercialisation while at Pfizer. The drug generates 8 billion in sales and Pfizer themselves will be watching closely as ACW and Xanamem move into their landmark Phs 2 trials. We could see significant news in September around Phs2 trials which should lead to significant media attention and with the press talking up the need for more drugs for patients in the Alzheimer's space its time to take a position here and hold for a potential significant re-rate.